Livforsakringsbolaget Skandia, Omsesidigt Nektar Therapeutics Call Options Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.85 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NKTR
# of Institutions
152Shares Held
130MCall Options Held
92.7KPut Options Held
4.9K-
Black Rock Inc. New York, NY15.2MShares$13 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$10.6 Million0.0% of portfolio
-
Samlyn Capital, LLC New York, NY9.67MShares$8.31 Million0.14% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.81MShares$6.72 Million0.37% of portfolio
-
Acadian Asset Management LLC Boston, MA7.2MShares$6.19 Million0.02% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $161M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...